Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34670329/

CDK4 & CDK6 are essential regulators of initial cell cycle phases and are always considered an exciting choice for anti-cancer therapy. In the present study, we presented the structure-based rational...

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34471951/

The differential prevalence of ctDNA-based alterations such as FGFR1, AKT1, and CDH1 was observed in initially HR+/HER2- MBC patients in the US vs. CN. In addition, the association of PTEN...

Evolution of HER2-low expression from primary to recurrent breast cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34642348/

About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution...

Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34653725/

doi: 10.1016/j.breast.2021.10.001. Online ahead of print. 1 Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2 Department of Medicine, Division of Hematology Oncology, Perelman...

Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34656740/

Abemaciclib+ET significantly improved IDFS in patients with HR+, HER-, node-positive, high risk EBC, with an acceptable safety profile. Ki-67 index was prognostic, but abemaciclib benefit was observed regardless of Ki-67...